title: Serum IL-6, IL-8, IL-10 and beta2-microglobulin in association with International Prognostic Index in diffuse large B cell lymphoma.
abstract: OBJECTIVE
  Diffuse large B-cell lymphoma displays striking heterogeneity at clinical, genetic and molecular levels. The International Prognostic Index is useful to predict the outcome of diffuse large B-cell lymphoma patients. However, patients with identical International Prognostic Index values in clinical practice exhibit marked variability in survival, suggesting the presence of significant residual heterogeneity within each category. Since cytokines such as interleukin-6, -8 and -10 play important roles in the pathogenesis of lymphomas, and plasma level of beta2-microglobulin is associated with the outcome of patients with diffuse large B-cell lymphoma, the aim of the present study was to determine whether these parameters combined with the International Prognostic Index would better stratify these patients to predict their prognosis.
  
  
  METHODS
  The study included 46 untreated diffuse large B-cell lymphoma patients.
  
  
  RESULTS
  All study parameters (International Prognostic Index, Ann Arbor stage, extranodal involvement, performance status, lactate dehydrogenase, beta2-microglobulin, interleukin-6 and -10, and response to therapy) except for patient age and serum interleukin-8 level were associated with overall survival. In addition, the International Prognostic Index was strongly correlated with beta2-microglobulin, interleukin-6, -8 and -10, and when combined these parameters significantly better stratified patients according to survival. On multivariate analysis, therapeutic response to the primary treatment, elevated interleukin-6 and -10 levels, and the International Prognostic Index were significant predictors of overall survival.
  
  
  CONCLUSIONS
  Our data imply that interleukins and beta2-microglobulin evaluation should be used in association with the International Prognostic Index to define prognostic subgroups in diffuse large B-cell lymphoma patients.
authors.affiliation: Department of Hematology, Clinical Hospital Center Rijeka, School of Medicine, Rijeka, Croatia. bmarijic@gmail.com
authors.forename: Antica
authors.initials: A
authors.lastname: Duletić-Nacinović
authors.forename: Sanja
authors.initials: S
authors.lastname: Stifter
authors.forename: Blazen
authors.initials: B
authors.lastname: Marijić
authors.forename: Ksenija
authors.initials: K
authors.lastname: Lucin
authors.forename: Toni
authors.initials: T
authors.lastname: Valković
authors.forename: Duska
authors.initials: D
authors.lastname: Petranović
authors.forename: Nives
authors.initials: N
authors.lastname: Jonjić
mesh_terms: D005260:Female; D006801:Humans; D016753:Interleukin-10 / Q000097:blood*; D015850:Interleukin-6 / Q000097:blood*; D016209:Interleukin-8 / Q000097:blood*; D053208:Kaplan-Meier Estimate; D016403:Lymphoma, Large B-Cell, Diffuse / Q000097:blood* / Q000401:mortality / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D011237:Predictive Value of Tests; D011379:Prognosis; D012044:Regression Analysis; D012720:Severity of Illness Index; D001613:beta 2-Microglobulin / Q000097:blood*
chemical_list: D015850:Interleukin-6; D016209:Interleukin-8; D001613:beta 2-Microglobulin; D016753:Interleukin-10